排序方式: 共有38条查询结果,搜索用时 15 毫秒
1.
多发性硬化患者血清尿酸水平变化的研究 总被引:2,自引:0,他引:2
目的 探讨多发性硬化 (MS)患者血清尿酸 (UA)水平的变化及其临床意义。方法 采用酶定量分析法对 4 3例MS患者和 4 5名正常对照者的血清UA水平进行检测。结果 MS组血清UA水平明显低于对照组 (P <0 0 1)。MS组中病程越长 (P <0 0 1)、神经伤残程度越重 (DSS评分越高 ) (P <0 0 5 ) ,血清UA水平越低 ;女性患者UA水平明显低于男性患者 (P <0 0 0 1) ;经过糖皮质激素治疗后血清UA水平明显回升 (P <0 0 0 1) ,但治疗前血清UA水平越低则疗效越差 (P <0 0 1、P <0 0 5 )。结论 MS患者血清UA水平降低 ,且与MS的病程、伤残程度、疗效及性别密切相关。UA水平升高可能为激素治疗MS的一个作用机制 相似文献
2.
3.
4.
Objective To investigate the predictive value of breast cancer susceptibility gene 1 (BRCA1) and class Ⅲβ-tubulin protein expression in tumor tissue for the efficacy of taxol and cisplatin combined chemotherapy (TP) in stage Ⅲβ/Ⅳ non-small cell lung cancer(NSCLC) patients. Methods A total of 92 stage Ⅲβ/Ⅳ NSCLC patients were recruited with 87 patients evaluated. Bronchoscopy or lung puncture tumor biopsy samples were obtained with BRCA1 and class Ⅲβ-tubulin protein expression examined immunohistochemically before chemotherapy. The patients were randomly assigned to be received 4 to 6 cycles of TP chemotherapy regiments and followed up until death or lost. Response rate (RR) , overall survival (OS) and time to tumor progression (TTP) were assessed. Results Among the 87 evaluated patients, the positive expression rates of BRCA1 and class Ⅲβ-tubulin were 57. 5% (50/87) and 48. 3%(42/87) respectively. There was no significant difference in clinical characteristics among patients with different positive expression rate. According to different expression of BRCA1 and class Ⅲβ-tubulin, the patients were divided into four groups: group A (low expression of both BRCA1 and class 1 p-tubulin) ,group B (high expression of both BRCA1 and class Ⅲβ-tubulin) , group C (high expression of only BRCA1) and group D (high expression of only class Ⅲβ-tubulin). The RR was higher in group A than other three groups (60. 7% , 34. 8% , 9/19 and 6/17 respectively). The OS and TTP were longer in group A than other three groups [OS: (539. 4 ± 17. 6) days, (267. 2 ± 20. 5) days, (325. 6 ± 24. 1) days and (283.7±26.2) days respectively ; TTP: (256. 9 ± 28. 4) days, (143.8±17.6) days, (179. 3 ± 19. 8)days and (152. 6 ±23. 5) days respectively]. There were no significant differences among the other three groups. Conclusions The expression level of BRCA1 and class Ⅲβ-tubulin in tumor tissue is probably a predictor for the efficacy of TP chemotherapy in NSCLC patients. TP chemotherapy is more suitable for the NSCLC patients with lower expression of both BRCA1 and class Ⅲβ-tubulin. Our study may provide a new sight for tailored chemotherapy in NSCLC patients. 相似文献
5.
6.
维生素D水平变化与多发性硬化的发生有密切的关系,维生素D受体基因多态性与多发性硬化相关。维生素D的活性形式骨化三醇可以预防多发性硬化的模型——实验性变态反应性脑脊髓炎或阻断其进展。对维生素D进行深入研究,对寻找防治多发性硬化的新药具有重要意义。 相似文献
7.
目的:观察多西紫杉醇(DOC)联合奥沙利铂(L-OHP)和5-氟尿嘧啶(5-Fu)的DOF方案治疗晚期胃癌的临床疗效和不良反应?方法:化疗方案 DOC 75 mg/m2(第1天),L-OHP 130 mg/m2(第1天),5-Fu 2.5 g/m2,持续静脉滴注120 h,21 d为1个周期,至少应用2个周期,进行疗效评价并评估反应?结果:全组73例均可评价疗效,总有效率为68.5%,其中完全缓解(CR)18例(24.7%),部分缓解(PR)32例(43.8%),至肿瘤进展时间为9.2个月,中位生存期为13.7个月?初治的46例有效率为76.1%,复治的27例有效率为55.5%?主要不良反应为骨髓抑制?口腔黏膜炎和周围神经毒性反应,其中Ⅲ~Ⅳ度白细胞下降率为26.0%,无治疗相关性死亡?结论:DOF方案是晚期胃癌的有效化疗方案,不良反应易于耐受? 相似文献
8.
目的 观察国产多西紫杉醇联合低剂量氟尿嘧啶(5-Fu)持续静脉输注治疗中晚期食管癌的近期疗效和毒副反应.方法 20例中晚期食管癌患者行此方案化疗,多西紫杉醇40 mg/(m2·d),静脉滴注1 h,第1,8天;5-Fu 250 mg/(m2·d),低剂量持续泵静脉输注24 h,连用14 d.以上方案每4周为1周期,2周期观察近期疗效和毒副反应.结果 20例患者均可评价疗效,其中CR 1例,PR 10例,SD 5例,PD 4例,总有效率55.0%(11 / 20).主要毒副反应为骨髓抑制,非血液学毒性轻微.结论 多西紫杉醇联合5-Fu低剂量持续泵静脉输注治疗中晚期食管癌具有较好疗效,副反应轻,耐受性好. 相似文献
9.
目的观察EPOCH方案治疗侵袭性非霍奇金淋巴瘤(NHL)的疗效和副作用。方法31例非霍奇金淋巴瘤患者采用EPOCH方案治疗。EPOCH方案:依托泊苷(VP-16)50mg/m2,表柔比星(E.ADM)12mg/m2,长春新碱(VCR)0.4mg/m2,溶解于生理盐水500ml中,持续静滴24h,第1~4天;环磷酰胺(CTX)750mg/m2静脉推注,第5天;强地松60mg/m2,口服,第1~5天,21天为1个周期,共进行4—6个周期。结果31例患者总有效率为90.3%,完全缓解(CR)率为64.5%,部分缓解(PR)率为25.8%,主要不良反应为骨髓抑制、脱发、黏膜炎。结论EPOCH方案是NHL经济、有效的治疗方案,毒性可耐受,值得在临床上推广应用。 相似文献
10.
目的探讨特发性无精子症及少弱精子症不育男性与Y染色体AZF微缺失的关系.方法用双重PCR技术对63例患者(无精于症41例,少弱精子症14例,严重少精子症8例)进行Y染色体AZFa、AZFb、AZFc、SRY的微缺失筛查.同时对26例无精于症患者行睾丸活检、组织学评估.结果63例中AZF微缺失7例,缺失率为11.1%.其中无精子症5例,严重少精子症2例.AZFc缺失4例,AZFb缺失2例,AZFb AZFc缺失1例,未发现AZFa区缺失.63例及对照组30例SRY基因扩增均阳性.26例无精子症患者行睾丸活检、组织学检查,无1例精子发生正常.结论Y染色体微缺失,特别是AZFc区DAZ基因的微缺失,是引起无精子和严重少弱精子等生精障碍而致男性不育较为重要的遗传学因素. 相似文献